Pops F. Richard's most recent trade in Neurocrine Biosciences, Inc. was a trade of 3,318 Restricted Stock Unit done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,318 | 3,318 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,869 | 34,480 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,869 | 0 | - | - | Restricted Stock Unit | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 293,921 | 293,921 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 190,640 | 1,370,315 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 79,925 | 1,290,390 (0%) | 0% | 31.4 | 2,508,846 | Ordinary Shares |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,869 | 2,869 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 4,199 | 33,711 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 4,199 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Sale of securities on an exchange or to another person at price $ 141.84 per share. | 17 May 2024 | 2,100 | 31,611 (0%) | 0% | 141.8 | 297,860 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 13 Mar 2024 | 23,200 | 52,712 (0%) | 0% | 42.8 | 992,032 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 23,200 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Sale of securities on an exchange or to another person at price $ 140.33 per share. | 13 Mar 2024 | 23,200 | 29,512 (0%) | 0% | 140.3 | 3,255,621 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 08 Mar 2024 | 1,700 | 31,212 (0%) | 0% | 42.8 | 72,692 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 1,700 | 23,300 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Sale of securities on an exchange or to another person at price $ 140.05 per share. | 08 Mar 2024 | 1,700 | 29,512 (0%) | 0% | 140.0 | 238,078 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 100 | 23,200 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 08 Mar 2024 | 100 | 29,512 (0%) | 0% | 140 | 14,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 08 Mar 2024 | 100 | 29,612 (0%) | 0% | 42.8 | 4,276 | Common Stock |
| Alkermes plc | Pops F. Richard | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 274,328 | 274,328 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard Pops F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 7,644 | 389,844 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 7,168 | 365,634 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | F. Pops Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 6,843 | 349,030 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Pops F. Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,999 | 305,999 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,980 | 305,024 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,899 | 300,899 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,697 | 290,570 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Pops F. Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 4,599 | 234,599 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 3,999 | 203,999 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard Pops F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 3,999 | 203,999 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 2,419 | 123,419 | - | - | Employee Stock Option (Right to Buy) | |
| Neurocrine Biosciences, Inc. | F. Richard Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | F. Richard Pops | Director | Sale of securities on an exchange or to another person at price $ 132.47 per share. | 20 Feb 2024 | 15,000 | 29,512 (0%) | 0% | 132.5 | 1,987,047 | Common Stock |
| Neurocrine Biosciences, Inc. | Pops Richard F. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 20 Feb 2024 | 15,000 | 44,512 (0%) | 0% | 13.0 | 194,700 | Common Stock |
| Alkermes plc | F. Richard Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 218,551 | 1,271,432 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | F. Pops Richard | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 91,757 | 1,179,675 (0%) | 0% | 26.8 | 2,456,335 | Ordinary Shares |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,199 | 4,199 | - | - | Restricted Stock Unit | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 284,873 | 284,873 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 119,713 | 1,088,012 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.07 per share. | 20 Feb 2023 | 53,145 | 1,034,867 (0%) | 0% | 28.1 | 1,491,780 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 32,400 | 1,067,267 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 32,400 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.77 per share. | 20 Feb 2023 | 14,386 | 1,052,881 (0%) | 0% | 27.8 | 399,499 | Ordinary Shares |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Sale of securities on an exchange or to another person at price $ 119.20 per share. | 03 Jan 2023 | 15,000 | 29,512 (0%) | 0% | 119.2 | 1,788,045 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 03 Jan 2023 | 15,000 | 44,512 (0%) | 0% | 12.7 | 190,650 | Common Stock |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.55 per share. | 05 May 2022 | 329,153 | 1,194,709 (0%) | 0% | 16.5 | 5,447,482 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 329,153 | 120,847 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 05 May 2022 | 221,222 | 973,487 (0%) | 0% | 28.0 | 6,183,243 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.55 per share. | 05 May 2022 | 120,847 | 1,062,046 (0%) | 0% | 16.6 | 2,000,018 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 120,847 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 27.85 per share. | 05 May 2022 | 93,747 | 968,299 (0%) | 0% | 27.9 | 2,611,313 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 05 May 2022 | 32,288 | 941,199 (0%) | 0% | 28.6 | 923,227 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 299,044 | 299,044 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 32,400 | 32,400 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 32,400 | 879,942 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.08 per share. | 18 Feb 2022 | 14,386 | 865,556 (0%) | 0% | 25.1 | 360,801 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 18,125 | 855,580 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 18,125 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.79 per share. | 16 Feb 2022 | 8,038 | 847,542 (0%) | 0% | 26.8 | 215,338 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2021 | 81,682 | 873,722 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.60 per share. | 14 Sep 2021 | 36,267 | 837,455 (0%) | 0% | 30.6 | 1,109,770 | Ordinary Shares |
| Neurocrine Biosciences, Inc. | Richard F. Pops | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.10 per share. | 18 May 2021 | 150,000 | 942,040 (0%) | 0% | 18.1 | 2,715,750 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 150,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 18 May 2021 | 150,000 | 792,040 (0%) | 0% | 21.9 | 3,285,405 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.10 per share. | 11 May 2021 | 150,000 | 942,040 (0%) | 0% | 18.1 | 2,715,750 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 21.95 per share. | 11 May 2021 | 89,703 | 852,337 (0%) | 0% | 21.9 | 1,968,541 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 22.30 per share. | 11 May 2021 | 60,297 | 792,040 (0%) | 0% | 22.3 | 1,344,798 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.10 per share. | 06 May 2021 | 100,000 | 892,040 (0%) | 0% | 18.1 | 1,810,500 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2021 | 100,000 | 300,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Sale of securities on an exchange or to another person at price $ 21.79 per share. | 06 May 2021 | 100,000 | 792,040 (0%) | 0% | 21.8 | 2,179,410 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 342,187 | 342,187 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 32,400 | 806,426 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 32,400 | 64,800 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.58 per share. | 21 Feb 2021 | 14,386 | 792,040 (0%) | 0% | 19.6 | 281,678 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 18,125 | 18,125 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 18,125 | 777,219 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 8,750 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 8,750 | 777,895 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.79 per share. | 16 Feb 2021 | 8,074 | 769,145 (0%) | 0% | 19.8 | 159,784 | Ordinary Shares |
| Alkermes plc | Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.97 per share. | 16 Feb 2021 | 3,869 | 774,026 (0%) | 0% | 20.0 | 77,264 | Ordinary Shares |